King's College London

Research portal

Using Real‐World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study

Research output: Contribution to journalArticle

Standard

Using Real‐World Data to Guide Ustekinumab Dosing Strategies for Psoriasis : A Prospective Pharmacokinetic‐Pharmacodynamic Study. / Pan, Shan; Tsakok, Teresa; Dand, Nick; Baudry, David Thomas; Duckworth, Michael James; Mahil, Satveer Kaur; Pushpa-Rajah, Angela Louise; Russell, Alice Elizabeth; Barker, Jonathan Nicholas William Noel; Smith, Catherine H.

In: Clinical and Translational Science, Vol. 13, No. 2, 03.2020, p. 400-409.

Research output: Contribution to journalArticle

Harvard

Pan, S, Tsakok, T, Dand, N, Baudry, DT, Duckworth, MJ, Mahil, SK, Pushpa-Rajah, AL, Russell, AE, Barker, JNWN & Smith, CH 2020, 'Using Real‐World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study', Clinical and Translational Science, vol. 13, no. 2, pp. 400-409. https://doi.org/10.1111/cts.12725

APA

Pan, S., Tsakok, T., Dand, N., Baudry, D. T., Duckworth, M. J., Mahil, S. K., Pushpa-Rajah, A. L., Russell, A. E., Barker, J. N. W. N., & Smith, C. H. (2020). Using Real‐World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study. Clinical and Translational Science, 13(2), 400-409. https://doi.org/10.1111/cts.12725

Vancouver

Pan S, Tsakok T, Dand N, Baudry DT, Duckworth MJ, Mahil SK et al. Using Real‐World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study. Clinical and Translational Science. 2020 Mar;13(2):400-409. https://doi.org/10.1111/cts.12725

Author

Pan, Shan ; Tsakok, Teresa ; Dand, Nick ; Baudry, David Thomas ; Duckworth, Michael James ; Mahil, Satveer Kaur ; Pushpa-Rajah, Angela Louise ; Russell, Alice Elizabeth ; Barker, Jonathan Nicholas William Noel ; Smith, Catherine H. / Using Real‐World Data to Guide Ustekinumab Dosing Strategies for Psoriasis : A Prospective Pharmacokinetic‐Pharmacodynamic Study. In: Clinical and Translational Science. 2020 ; Vol. 13, No. 2. pp. 400-409.

Bibtex Download

@article{0e493c9a9db3488e94f3c961333ce5de,
title = "Using Real‐World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study",
abstract = "Variation in response to biologic therapy for inflammatory diseases, such as psoriasis, is partly driven by variation in drug exposure. Real-world psoriasis data were used to develop a pharmacokinetic/pharmacodynamic (PK/PD) model for the first-line therapeutic antibody ustekinumab. The impact of differing dosing strategies on response was explored. Data were collected from a UK prospective multicenter observational cohort (491 patients on ustekinumab monotherapy, drug levels, and anti-drug antibody measurements on 797 serum samples, 1,590 measurements of Psoriasis Area Severity Index (PASI)). Ustekinumab PKs were described with a linear one-compartment model. A maximum effect (E max) model inhibited progression of psoriatic skin lesions in the turnover PD mechanism describing PASI evolution while on treatment. A mixture model on half-maximal effective concentration identified a potential nonresponder group, with simulations suggesting that, in future, the model could be incorporated into a Bayesian therapeutic drug monitoring “dashboard” to individualize dosing and improve treatment outcomes. ",
author = "Shan Pan and Teresa Tsakok and Nick Dand and Baudry, {David Thomas} and Duckworth, {Michael James} and Mahil, {Satveer Kaur} and Pushpa-Rajah, {Angela Louise} and Russell, {Alice Elizabeth} and Barker, {Jonathan Nicholas William Noel} and Smith, {Catherine H}",
year = "2020",
month = mar,
doi = "10.1111/cts.12725",
language = "English",
volume = "13",
pages = "400--409",
journal = "Clinical and Translational Science",
issn = "1752-8054",
publisher = "Wiley",
number = "2",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Using Real‐World Data to Guide Ustekinumab Dosing Strategies for Psoriasis

T2 - A Prospective Pharmacokinetic‐Pharmacodynamic Study

AU - Pan, Shan

AU - Tsakok, Teresa

AU - Dand, Nick

AU - Baudry, David Thomas

AU - Duckworth, Michael James

AU - Mahil, Satveer Kaur

AU - Pushpa-Rajah, Angela Louise

AU - Russell, Alice Elizabeth

AU - Barker, Jonathan Nicholas William Noel

AU - Smith, Catherine H

PY - 2020/3

Y1 - 2020/3

N2 - Variation in response to biologic therapy for inflammatory diseases, such as psoriasis, is partly driven by variation in drug exposure. Real-world psoriasis data were used to develop a pharmacokinetic/pharmacodynamic (PK/PD) model for the first-line therapeutic antibody ustekinumab. The impact of differing dosing strategies on response was explored. Data were collected from a UK prospective multicenter observational cohort (491 patients on ustekinumab monotherapy, drug levels, and anti-drug antibody measurements on 797 serum samples, 1,590 measurements of Psoriasis Area Severity Index (PASI)). Ustekinumab PKs were described with a linear one-compartment model. A maximum effect (E max) model inhibited progression of psoriatic skin lesions in the turnover PD mechanism describing PASI evolution while on treatment. A mixture model on half-maximal effective concentration identified a potential nonresponder group, with simulations suggesting that, in future, the model could be incorporated into a Bayesian therapeutic drug monitoring “dashboard” to individualize dosing and improve treatment outcomes.

AB - Variation in response to biologic therapy for inflammatory diseases, such as psoriasis, is partly driven by variation in drug exposure. Real-world psoriasis data were used to develop a pharmacokinetic/pharmacodynamic (PK/PD) model for the first-line therapeutic antibody ustekinumab. The impact of differing dosing strategies on response was explored. Data were collected from a UK prospective multicenter observational cohort (491 patients on ustekinumab monotherapy, drug levels, and anti-drug antibody measurements on 797 serum samples, 1,590 measurements of Psoriasis Area Severity Index (PASI)). Ustekinumab PKs were described with a linear one-compartment model. A maximum effect (E max) model inhibited progression of psoriatic skin lesions in the turnover PD mechanism describing PASI evolution while on treatment. A mixture model on half-maximal effective concentration identified a potential nonresponder group, with simulations suggesting that, in future, the model could be incorporated into a Bayesian therapeutic drug monitoring “dashboard” to individualize dosing and improve treatment outcomes.

U2 - 10.1111/cts.12725

DO - 10.1111/cts.12725

M3 - Article

VL - 13

SP - 400

EP - 409

JO - Clinical and Translational Science

JF - Clinical and Translational Science

SN - 1752-8054

IS - 2

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454